Mitochondrial Dysfunction in Bipolar Disorder: 
Lessons from Brain Imaging and Molecular Markers

Luciano Minuzzi, MD, PhD1,2 
Guilherme Antônio Behr, MSc1,2,3,4 
José Cláudio Fonseca Moreira, PhD3 
Benicio N. Frey, MD, PhD1,2

Abstract

Bipolar disorder (BD) is a chronic major mental illness characterized by extreme mood episodes, cognitive impairment, and high rates of disability. Several lines of evidence suggest that BD may be associated with abnormalities in mitochondrial function. Here we critically review findings from brain imaging and from preclinical studies that investigated markers of energy metabolism in BD. Research with postmortem brain and peripheral tissue revealed changes in size and distribution of mitochondria, as well as decreased mitochondrial electron transport chain function, increased oxidative stress, and increased lipid and protein damage. PET imaging studies revealed decreased glucose metabolism in sub-areas of the prefrontal cortex, amygdala, and hippocampus structures in BD. On the other hand, increased lactate levels in BD have been found in cerebrospinal fluid and in gray matter by magnetic resonance spectroscopy, which suggest that distinct pathophysiological processes may be region-specific. Resting state fMRI studies have demonstrated decreased functional connectivity between fronto-limbic circuits. In conclusion, these results support the hypothesis of mitochondrial dysfunction in BD and suggest that BD is associated with decreased energy production and a shift towards anaerobic glycolysis. Such changes in energy metabolism can potentially decrease cell plasticity and ultimately disrupt brain circuits associated with mood and cognitive control.

Key words: Mitochondrial dysfunction, bipolar disorder, PET, biomarkers.

Título: Disfunción mitocondrial en el trastorno bipolar: lecciones de las imágenes cerebrales y los marcadores moleculares

1 Mood Disorders Program, Department of Psychiatry and Behavioural Neurosciences, McMaster University, Hamilton, ON, L8P 3B6, Canada. 
2 Women’s Health Concerns Clinic, St. Joseph’s Healthcare, Hamilton, ON, L8P 3B6, Canada. 
3 Center of Oxidative Stress Research, Professor Tuiskon Dick Department of Biochemistry, Institute of Health Basic Sciences, Federal University of Rio Grande do Sul (UFRGS), Av. Ramiro Barcelos, 2600 - Anexo, CEP 90035-003 Porto Alegre, RS, Brazil. 
4 Capes Foundation, Ministry of Education of Brazil. Caixa Postal 250, CEP 70040-020, Brasília, DF, Brazil
Introduction

Bipolar disorder (BD) is a chronic and disabling major mental illness characterized by episodic disturbances in mood reactivity (e.g. mania, depression) and cognitive impairment. Even though BD is associated with structural and functional brain changes, the fact that BD is also associated with increased mortality due to general medical conditions such as heart disease and cancer (1), as well as higher risk for metabolic syndrome, suggests that BD is a systemic rather than a brain-limited disorder (2). Over the past decade, there has been converging evidence supporting the hypothesis of mitochondrial dysfunction as a key element in the pathophysiology of BD (3-5). The brain metabolizes approximately 20% of all of the body’s oxygen because it works under a constant high energy demand. Considering that most of the energy produced in the brain is used to replenish the ATP consumed by the Na-K-ATPase pump and in the production/metabolism of neurotransmitters, mitochondrial dysfunction may disrupt the membrane’s ionic gradient and the glutamatergic clearance, thereby leading to abnormal neuronal firing. Furthermore, persistent glutamatergic activity may lead to a state of excitotoxicity and potentially cell death.

Here we critically review studies conducted with postmortem brain tissue, peripheral blood and studies in vitro that provide evidence of mi-
mitochondrial dysfunction in BD, as well as data from positron emission tomography, resting state functional magnetic resonance imaging and magnetic resonance spectroscopy that assessed energy metabolism in individuals with BD in vivo.

**Molecular Markers of Mitochondrial Dysfunction**

Evidence of mitochondrial dysfunction in BD is suggested by altered mitochondrial morphology, impaired brain energy metabolism, altered mitochondria-dependent Ca2+ signaling, the effects of mood stabilizers on mitochondria, increased mitochondrial DNA deletion in the neural tissue of BD patients, and the association of mitochondrial DNA mutations and/or polymorphisms with BD (4-6).

Morphological changes of mitochondria have been observed in the central nervous system (CNS) as well as in peripheral tissue in individuals with BD. Mitochondria from patients with BD exhibited size and distributional abnormalities compared with psychiatrically-healthy age-matched controls. Specifically, in the prefrontal cortex, individual mitochondrial profiles had significantly smaller areas in individuals with BD (7). In two peripheral cell types (fibroblasts and lymphocytes) the mitochondria from BD individuals exhibited alterations in distribution and morphology, showed by dense or bulky networks with perinuclear clustering profile. This study was the first to demonstrate that brain cortical and also peripheral cells from BD patients display abnormalities in the morphology (size and shape) and in the intracellular distribution of mitochondria. Given that abnormal mitochondrial morphology is linked to altered energy metabolism, changes in mitochondrial size and distribution may lead to energy deficits and, therefore, may have consequences for cell plasticity, resilience, and survival in patients with BD.

Abnormalities in mitochondrial function have also been observed in BD. A recent postmortem study reported a reduction in the activity of the complex I of the mitochondrial electric transport chain (ETC) in the prefrontal cortex in BD, but not in schizophrenia (SZ) or major depressive disorder (MDD), and this reduction was associated with increased protein oxidative damage (8). Prolonged impairment in oxidative phosphorylation activity causes accumulation of lactate and unprocessed glucose. Consistent with this, a study found increased lactate in the cerebrospinal fluid of BD patients, which indicates a shift from mitochondrial respiration to anaerobic glycolysis (9). Some data suggest that cellular response to metabolic stress may be impaired in BD, and such impairment may be closely linked to mitochondrial function. For instance, the molecular response to glucose deprivation in lymphocytes of BD patients was significantly re-
duced as compared to cells of normal controls (10). Microarray analysis of the peripheral blood mononuclear cells revealed that control subjects upregulated expression of ETC genes in response to glucose deprivation, while cells from BD patients failed to show any changes in mitochondrial gene expression (10). Together, these studies suggest that alterations in the ETC within the mitochondria may be associated with a shift from oxidative phosphorylation to anaerobic glycolysis in BD. In this context, a preliminary study revealed that the mood stabilizer lithium can increase the activity of mitochondrial ETC complexes I/II and II/III in human brain tissue (11), which suggests that lithium may stabilize mitochondrial function.

Creatine kinase (CK) is a key enzyme involved in the transport of ATP from mitochondria to cytosol. An elegant study conducted by MacDonald et al (2006) found that CK mRNA were downregulated in the hippocampus and dorsolateral prefrontal cortex in BD (12). Considering the central role of CK in the transport of intracellular high-energy phosphates, this study revealed another indicative of altered energy metabolism in specific brain areas in BD. However, one study conducted in rats reported that neither lithium nor valproate were able to reverse or prevent the inhibition of CK activity induced by amphetamine (13).

Several lines of evidence suggest that BD may be associated with altered Ca2+ signaling. Since mitochondria buffer cytosolic Ca2+, abnormal Ca2+ homeostasis may induce detrimental effects on mitochondrial and cell function and viability (14,15). In addition, the interplay between elevated intracellular Ca2+ concentration, reactive oxygen species (ROS) formation, and mitochondrial dysfunction has been long associated with brain pathology (3, 14). Studies with peripheral blood found elevated Ca2+ levels in platelets and lymphocytes of BD patients (16-18). Also, lymphoblastoid cell lines derived from BD patients showed higher Ca2+ peaks after thapsigargin, thrombin- or lysophosphatidic acid-mediated stimulation (17,19). Chronic lithium treatment attenuates intracellular calcium mobilization in B lymphoblast cell lines (20). In this context, it has been hypothesized that elevated intracellular Ca2+ levels when associated with mitochondrial dysfunction and subsequent decreased ATP production may reduce the ability of neuronal cells to appropriately respond to temporary peaks in stressful stimuli such as increased glutamate release during emotional distress (21).

Oxidative stress refers to the cytotoxic consequences of excessive generation of ROS – superoxide anion (O2−), hydrogen peroxide (H2O2), and hydroxyl radical (OH·) (22). Under normal circumstances, ROS are eliminated by enzymatic (i.e. superoxide dismutase, SOD; catalase, CAT; glutathione peroxi-
dase, GPx) and non-enzymatic antioxidant defences (i.e. vitamins; glutathione, GSH). When these antioxidant systems are outweighed by extreme levels of ROS, there is a higher potential for damage to DNA, lipids (i.e. cell and organelle membranes) and proteins (i.e. receptors, transcription factors and enzymes) (23). A number of studies reported increased oxidative damage in both peripheral blood and postmortem brain of BD patients (6,24). For instance, one study found a remarkably high frequency of DNA damage (as measured by DNA fragmentation using the comet assay) in peripheral blood of BD subjects relative to controls and that the frequency of DNA damage correlated with the severity of manic and depressive symptoms (25). Consistent with this finding, a postmortem study found that DNA fragmentation is also increased in non-GABAergic neurons in the anterior cingulate cortex in individuals with BD (26). Another consistent finding that has been replicated by several laboratories is increased lipid peroxidation (lipid damage) in BD. Increased levels of 4-hydroxynonenal, a product of lipid peroxidation, were found in the anterior cingulate cortex of subjects with BD and SZ (27). Several studies have reported increased levels of thiobarbituric acid reactive substances (TBARS) in both plasma (28) and serum samples (29-33). Notably, treatment with lithium and valproate at therapeutically relevant concentrations significantly inhibited glutamate-induced increased intracellular Ca+2, lipid peroxidation, protein oxidation, DNA fragmentation, and cell death in primary cultured rat cerebral cortical cells (34,35). In addition, both of these mood stabilizers can also enhance mitochondrial function and protect against mitochondrially-mediated toxicity in SH-SY5Y neuron cell culture (36). Animal models using increased oxidative stress induced by amphetamine exposure found that lithium and valproate reversed and prevented amphetamine-induced TBARS formation in vivo (37). Consistent with this finding, another rat study showed that lithium and valproate were able to modulate the oxidative balance and prevent cerebral DNA damage (38).

Studies looking at antioxidant activity profile in BD patients have been less consistent. For instance, there are reports of increased SOD and CAT activities (31), unaltered SOD and decreased CAT activity (32,39), an imbalance between increased SOD and decreased CAT activities (29), increased GPx activity (29), and also decreased GPx activity (32) in the peripheral blood of BD subjects. A postmortem study showed decreased total GSH levels in prefrontal cortex of patients with BD, SZ and major depression (40). Furthermore, a case study that investigated the oxidative stress profile in two monozygotic twins during a manic episode showed that bipolar twins had higher TBARS, SOD and
DNA damage, and lower CAT. TBARS and SOD were normalized after mood stabilization, whereas CAT and DNA damage remained unaltered after 6 weeks of treatment (41). A recent meta-analysis confirmed that a consistent finding in BD patients is the presence of increased TBARS across all mood states (42). As far as the potential use of antioxidant agents, there are some encouraging data suggesting that N-acetyl cysteine (NAC), a precursor of glutathione, may be a useful adjunctive treatment in reducing oxidative stress, and improving clinical symptoms, quality of life, and functioning in individuals with BD (43, 44).

In summary, there is converging evidence from animal, clinical, and preclinical studies suggesting that BD is associated with altered Ca2+ signaling and gene expression, increased oxidative stress and DNA damage, and mitochondrial dysfunction. Studies in vitro and in vivo support that both lithium and valproate can stabilize mitochondrial function and prevent oxidative stress. Perhaps more importantly, some initial clinical trials support the use of antioxidants, such as NAC, as adjunctive in the treatment of BD.

**Brain Imaging and Energy Metabolism in BD**

*Positron Emission Tomography (PET)*

Brain metabolism can be measured by PET technique using a radio-labelled glucose analogue, [18F]-fluorodeoxyglucose (FDG). When FDG is taken up into the cell, it is metabolized by phosphorylation to FDG-6 phosphate and accumulates in the cell, providing an indirect measurement of the local glucose metabolism.

An early study with euthymic and drug-free BD patients and electrical stimulation showed a reduction of FDG uptake in frontal cortex, occipital cortex and basal ganglia compared to healthy controls (HC) (45). Using the subgenual region as region-of-interest (ROI), a population of depressive BD patients presented a reduction of the glucose metabolism in that area compared to HC (46). In the same sample, manic patients (n=4) revealed higher global FDG uptake. Subsequently, this finding has been independently replicated in a sample of depressed BD patients (47). In the amygdala no differences in glucose metabolism between depressive BD, HC and MDD patients were observed. However, individuals that were off-medication presented higher FDG uptake, which suggests that treatment may normalize over activity in the amygdala (48). A study with FDG and cerebral blood flow (CBF) in BD type I and type II patients showed a positive correlation between glucose metabolism and blood flow, but such correlation was less robust in comparison to HC. Also there was a negative correlation between glucose metabolism and CBF in the left pregenual ACC, indicating a local uncoupling flow-metabolism disrup-
tion that might suggest vasomotor or mitochondrial dysfunction (49). A recent FDG-PET study examined a population of depressed and euthymic women with BD type I, as compared to MDD and HC. This study showed a decrease of glucose metabolism in frontal gyri, right cingulate, inferior parietal cortex and angular gyri in BD patients. However, the euthymic BD patients did not display differences in these brain regions (50), which suggested that some metabolic changes may be state-related depending on the brain area. Another study found a reduction in bilateral dorsolateral prefrontal cortex (DLPFC) and left amygdala, and an increase in the left occipital cortex and right temporal cortex in manic subjects with psychosis. However this study used a “clinical diagnosis” rather than the DSM classification for the selection of the sample (51). Benson and col. reported a FDG study with treatment refractory depressed BD patients. In that study, correlation analysis across different brain regions showed higher metabolic association between the left DLPFC, left inferior parietal cortex, thalamus and insula and other brain regions in the BD sample compared to HC (52). These results are in conflict with previous report of global decrease in metabolism in depressed BD patients in comparison HC in DLPFC, insula, striatum, ACC, PFC and subgenual (53).

In summary, measurements of the brain metabolism with PET reported mostly a decrease in metabolic activity in several brain regions of BD patients in comparison to HC. Even though methodological limitations such as low sample size, heterogeneity of the BD population and lack of control of baseline glucose level may have skewed the results, the consistent finding of low FDG levels in the brain of BD cannot be ignored and suggest that a decrease in energy metabolism may be part of the pathophysiology of BD.

**Resting State fMRI**

Resting state functional MRI is a technique based on the study of low frequency blood oxygen level-dependent oscillations in the absence of any mental task while the subject rests quietly (54). Although the underlying brain activity revealed by this technique has been debatable, it has been suggested that it would identify brain regions that present functional connectivity across each other (55). To date, only four studies have looked at resting state fMRI technique in BD. In a study that included both manic and depressive BD patients, connectivity between pregenual anterior cingulate (pACC) and amygdala, and between thalamus and pallidostriatum were decreased in BD compared to HC, but were similar to MDD patients (56). Another study of manic and mixed BD I patients showed decreased activity in medial prefrontal cortex (MPFC) and the hippocampus as compared to HC (57). In a heterogeneous BD
population of rapid cyclers, euthymic, mixed, and depressive patients, BD subjects showed decreased connectivity between left ventral prefrontal cortex (VPFC) and left amygdala as well as between left VPFC and dorsolateral and parietal regions. The same study revealed increases in connectivity between left VPFC and contralateral hemisphere (58). In an euthymic pediatric population of BD patients, resting state fMRI revealed a decrease in the connectivity between left DLPFC and contra-lateral temporal gyrus. Using the superior temporal gyrus (STG) as seed point, BD pediatric patients showed decrease in the connectivity between STG and frontal gyri (superior and middle), and between STG and thalamus. However it was observed an increase in the connectivity between STG and parahippocampal gyrus in the patients in comparison to HC (59).

Overall, the preliminary studies of resting state fMRI suggest that individuals with BD present a decrease in the connectivity between a number of corticolimbic regions associated with mood and cognitive control. Whether such abnormal functional connectivity are part of the pathophysiology of the disease or part of a compensatory mechanism it remains to be determined.

**Magnetic Resonance Spectroscopy**

Magnetic resonance spectroscopy (MRS) is a non-invasive imaging technique that provides in vivo quantification of a number of metabolites in the brain. Single proton MRS (1H-MRS) enables measurement of glutamate (Glu), glutamine (Gln), N-acetyl-L-aspartate (NAA), choline compounds (Cho), creatine and phosphocreatine (Cre), myoinositol (ml) and lactate. For the purpose of reviewing brain energy metabolism status we will focus on the studies reporting absolute levels of these metabolites in the brain. Results describing differences in ratio of the metabolites (e.g., NAA/Cre, NAA/Cho, etc) will not be reviewed.

In mammals, glutamate is the main excitatory neurotransmitter in the CNS. It is synthetized in glutamatergic neurons and astrocytes (60). Measurements of glutamate (Glu), glutamine (Gln), and the combined Glu-Gln (Glx) provide information about the local glutamate metabolism. Higher or lower glutamate metabolites may indicate abnormalities in the local glutamatergic metabolism. A MRS study with a sample of manic and depressive BD patients found a decrease in Glx levels in the frontal cortex and basal ganglia, while there was no alteration in the thalamus (61). In contrast, another study revealed some brain areas with high levels of Glx such as MVPFC, insular cortex and cortical grey matter (62). BD patients in a manic phase did not display differences in Glu, Gln or Glx levels compared to HC in the ACC, parietal-occipital cortex (63) or OFC (64). However, the ratio Gln/
Glu was reported to be higher in the ACC and the parietal-occipital cortex of manic BD patients (63). To date, only one study examined BD patients during depressive state. Depressive BD patients presented an increase of Glu and Glx but not Gln in the ACC (65). Children with BD showed low Gln but not Glu in the ACC compared to HC (66). In asymptomatic children with one parent presenting BD, the Glu and Glx levels were compared to controls in the cerebellar vermis (67). Different treatments for BD have been tested to reveal changes in the glutamate levels in the brain. Pharmacotherapy with riluzole (68) and lithium (69) did not change the Gln/Glu and Glu and Gln levels in the ACC after treatment. However, lithium decreased Glx levels in grey matter of BD patients in comparison to valproate (70). The mood-stabilizer lamotrigine showed to increase Gln in the ACC and the MPFC of depressed BD patients (65). Treatment with quetiapine did not change Glx levels in the medial frontal cortex of rapid cyclic BD patients (71). In a sample of depressed BD patients, treatment with cytidine decreased Glu/Gln levels in the ACC in comparison to placebo (72).

Glutamate and glutamine levels as biomarkers for local glutamatergic function have shown higher activity in some cortical regions associated with mood and cognitive control (for instance, ACC and OFC). Considering that the glutamate-glutamine cycle is closely linked to energetic metabolism, these results further support that changes in energy metabolism are part of the pathophysiology of BD.

N-acetyl-L-aspartate (NAA) is produced in the mitochondria in the neuronal cell bodies and it is considered a marker of neuronal integrity (73). In heterogeneous samples of manic and depressive subjects, NAA has been found diminished only in the basal ganglia (61). Measurements in thalamus, frontal cortex white matter (61), anterior cingulate (ACC), insular cortex and grey matter (62) did not reveal differences in NAA levels compared to healthy controls (HC). In euthymic BD patients, it has been reported a decrease in NAA levels in hippocampus (74) and an increase in thalamus (75). Proton MRS studies on medial prefrontal cortex (MPFC) (76), frontal cortex (77), and basal ganglia (78) did not find differences in NAA levels in comparison to HC. BD patients, while in manic phase, showed decrease of NAA levels in the orbital frontal cortex (OFC) (64). However, other brain regions such as ACC (63,78), parietal-occipital cortex (63), dorsolateral prefrontal cortex (DLPFC) (79), and frontal cortex (78) did not reveal differences in NAA levels during manic phase in comparison to HC. Only two MRS studies have focused on NAA levels and BD patients during the depressive phase. These studies found no differences in NAA levels in the ACC (65) and frontal cortex (77). Children diagnosed with BD showed lower
levels of NAA in the DLPFC, MPFC (80) and cerebellum (81) compared to HC. No differences were found in NAA levels in the frontal cortex (81,82), posterior cingulate (PC) and occipital cortex (80) in the pediatric population with BD. Two studies in children focused on the ACC presented different results: NAA levels were found unchanged in an earlier study (83). Recently, in another study, it has been shown a decrease of NAA in the ACC of children with BD (80). Pharmacotherapy seems to affect the NAA levels in the brain of BD patients. Lithium (69), riluzole (68), and ethyl-EPA (84) showed to increase NAA concentration in cortical regions after treatment. Lamotrigine (65) produced a reduction in the NAA levels in the ACC of BD patients. Also in a pediatric BD sample, NAA levels in MVPFC but not in VLPFC decreased after treatment with lithium (85). Some pharmacological studies with quetiapine (71), valproate (70), and lithium (70,85) did not show any effect on NAA levels in different cortical regions.

Low NAA levels in the brain have been described in several neurodegenerative disorders (86). Hence a local decrease of NAA in the brain might be indicative of neuronal damage or death. In BD, some brain regions such as hippocampus, OFC and basal ganglia presented a reduction in NAA levels compared to HC, suggesting decreased neuronal integrity. Interestingly, studies in the pediatric population with BD have shown more brain regions with low NAA levels compared to HC, supporting the idea of BD as a neurodevelopmental disorder.

Creatine and phosphocreatine (Cre) are abundant in the brain. Creatine is produced in the liver and kidneys and it is transported into the brain, where it is converted to phosphocreatine in the mitochondria. Phosphocreatine is then transported to the cytosol and donates a phosphate group to ADP to replenish ATP. Hence, Cre levels may be used as a measure of energy utilization in the brain. Two MRS studies investigated Cre levels in heterogeneous groups of BD patients with both depressive and manic states. As with NAA, Cre presented diminished in the basal ganglia (61). Thalamus, frontal cortex white matter (61), anterior cingulate (ACC), insular cortex and grey matter (62) did not show differences in Cre levels in this population compared to HC. In euthymic BD patients, the results of Cre brain levels also followed the NAA levels: in the hippocampus, Cre levels were found diminished (74), whereas in thalamus Cre levels were found increased compared to HC (75). In euthymic BD, Cre levels were compared to HC in the frontal cortex and MPFC (76,77). While in manic BD patients, no changes in Cre levels were found in several brain regions (63, 64, 79), depressive BD patients presented higher Cre levels in the ACC (65) and lower levels in the frontal cortex (77).
with medication-free individuals with BD at various mood states, it has been reported a decrease in Cre levels in the left DLPFC (87). In pediatric BD, Cre levels have been found mostly decreased compared to HC in the ACC, DLPFC, MPFC (80) and cerebellum (81). In the ACC, another study failed to find differences in Cre levels in the same population (66). Also in children and adolescents with BD, Cre levels were normal in the frontal cortex (81), posterior cingulate and occipital cortex (80). Light therapy (88), lithium (61,70,85,89), ethyl-EPA (84), quetiapine (71), and risperidone (83) all failed to show any effect on Cre levels after treatment.

Creatine and phosphocreatine levels as biomarkers for energy consumption in the brain have demonstrated close relationship with NAA in the same brain regions. Although no alterations in Cre levels were found in manic subjects, BD depressive patients showed opposite changes in Cre levels in distinct areas of the PFC (higher Cre in ACC, lower Cre in frontal cortex). Lower Cre levels have been reported in the DLPFC in BD subjects free of medications but this finding needs replication. In early stages of brain development, studies with children diagnosed with BD consistently showed reduced levels of Cre in frontal cortical regions and cerebellum. Together these results suggest that the abnormalities in the Cre metabolism in the frontal regions in BD may be more pronounced during depression and early in the course of the disease.

Lactate is continuously produced during normal metabolism and may serve as a source of energy in conditions of decreased oxidative phosphorilation. Thus, increased levels of lactate may be an indicative of metabolic dysfunction. Lactate levels were higher in the grey matter of depressed or mixed BD type I and II. In the same sample, the analysis of subpopulation of BD type I patients revealed increase levels of lactate compared to HC (62). Lactate levels in ACC were unchanged after treatment with lithium (70). However, after treatment with quetiapine, manic BD patients showed a reduction in the lactate levels in the medial frontal cortex, with patients who responded to the treatment presenting higher decrease (71).

In vivo quantification of lactate in BD brain has been limited. The only study in medication-free patients suggests that increased lactate may be associated with a shift towards anaerobic glycolysis in the grey matter of BD type I.

Results from PET and resting state fMRI suggest that there are local metabolic abnormalities in the brain of BD patients. Most of the cortical brain regions have shown decrease in markers for energy metabolism in BD compared to HC. MRS studies suggest that BD is associated with impaired oxidative phosphorilation and a shift towards anaerobic energy production with subsequent
decrease in total energy production (5). In addition, markers for neuronal integrity have shown regional low levels in BD. Together, these studies suggest that a decrease in energy metabolism associated with mitochondrial dysfunction may impair the connectivity between brain regions (e.g. fronto-limbic circuit) which may, in turn, lead to mood and cognitive impairment observed in BD.

Conclusions

The data reviewed above provide strong support to the hypothesis of mitochondrial dysfunction in BD. Considering that the main physiological roles of mitochondria are related to oxidative phosphorylation, Ca2+ metabolism and apoptosis, it is remarkable that all of these components have been found abnormal in BD. Notably, abnormalities in the mitochondrial ETC, altered Ca2+ signaling, increased oxidative stress and DNA damage have been observed in peripheral blood and in postmortem brain tissue in BD. These findings suggest that, at least in some brain areas of individuals with BD (most notably sub-areas of the prefrontal cortex), there may be a decrease in mitochondrial oxidative phosphorylation, which may, in turn, cause a decrease in ATP production. If this hypothesis is true, then it expected an increase in the production of lactate and a shift towards anaerobic glycolysis. Indeed, increased lactate levels have been reported both in the CSF as well as in the brain (gray matter) of BD subject as measured by MRS in vivo. Studies with FDG-PET have demonstrated that a number of brain regions are associated with a decrease in glucose metabolism. But perhaps more importantly, initial results from resting state fMRI revealed abnormalities in functional connectivity between fronto-limbic areas associated with emotional and cognitive control.

Preliminary data suggest that lithium and, in a much less extent, valproate may help stabilizing mitochondrial function. There is also new data suggesting that the antioxidant agent NAC may be a useful adjunctive option in the treatment of BD. Whether or not the effects on mitochondrial function and oxidative stress are associated with their clinical response it remains to be determined. In the search for biomarkers of disease and treatment response, markers of energy metabolism and oxidative damage are promising candidates to understand the underlying neurobiology of BD. Ultimately, research in this field may help in the development of new treatment agents for this devastating major mental illness.

Acknowledgments

Dr. L. Minuzzi is a recipient of a CIHR/Wyeth Rx&D Research Fellowship award and Dr. G.A. Behr is recipient of Capes scholarship - Proc. nº BEX 5383/10-2.
References


55. Fox MD, Raichle ME. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat Rev Neurosci. 2007;8:700-11.


Mitochondrial Dysfunction in Bipolar Disorder: Lessons from Brain Imaging and Molecular Markers


84. Frangou S, Lewis M, Wollard J, et al. Preliminary in vivo evidence of increased N-acetyl-aspartate following eico-


Conflicts of interest: The authors have not conflicts of interest.

Recibido para evaluación: 28 de julio del 2011
Aceptar para publicación: 10 de agosto del 2011

Corresponding author
Benicio N. Frey
Capes Foundation
Ministry of Education of Brazil
Caixa Postal 250, CEP 70040-020
Brasilia, DF, Brazil
freybn@mcmaster.ca